Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
Health Services Management and Policy, The Ohio State University College of Public Health and Moritz College of Law, Columbus, Ohio, USA.
Tob Control. 2019 Dec;28(e2):e119-e125. doi: 10.1136/tobaccocontrol-2018-054537. Epub 2019 May 23.
Prior to the final deeming rule, federal law in the USA prohibited electronic cigarettes (e-cigarettes) from being marketed as smoking cessation products; for other therapeutic purposes and in ways that conveyed Food and Drug Administration (FDA) approval/endorsement. After August 2016, additional federal prohibitions were added including false/misleading and unauthorised modified risk tobacco product (MRTP) claims. No systematic investigation of e-cigarette health claims has been conducted in the retail environment. We sought to document and characterise claims made in vape shops.
Between November 2015 and February 2016, before final deeming rule implementation, two trained data collectors conducted unannounced observational assessments of 46 vape shops in North Carolina. Data collectors used wearable imaging technology to document health claims about e-cigarettes. Photos were coded for five claim types: (1) cessation device; (2) drug effect/device; (3) FDA-approved/endorsed; (4) false/misleading and (5) MRTP. Photos were double coded; differences between coders were adjudicated and reviewed by an expert panel.
At least one health claim was displayed in 41.3% (n=19) of retailers, ranging from 0 to 27 claims per retailer. All claim types were found. Cessation device claims were the most prevalent (62.2%, n=84), followed by MRTP (27.4%, n=37), drug effect/device (8.1%, n=11), false/misleading (1.5%, n=2), and FDA approved/endorsed (0.7%, n=1). Retail chains made the majority of claims compared with independent shops (88.9% vs 11.1%).
Many vape shops displayed e-cigarette health claims, which are all now FDA prohibited. These claims could mislead consumers and influence behaviour. Findings highlight the need for retailer education, continued surveillance, enforcement specific to advertising and research on consumer perceptions of claims.
在美国,联邦法律在最终的授权规则之前禁止电子烟(e-cigarettes)作为戒烟产品销售;禁止出于其他治疗目的或以传达食品和药物管理局(FDA)批准/认可的方式销售。2016 年 8 月之后,又增加了一些联邦禁令,包括虚假/误导性和未经授权的改良风险烟草产品(MRTP)声明。在零售环境中,尚未对电子烟健康声明进行系统调查。我们试图记录并描述蒸气商店中电子烟的健康声明。
在最终授权规则实施之前的 2015 年 11 月至 2016 年 2 月期间,两名经过培训的数据收集员对北卡罗来纳州的 46 家蒸气店进行了突击观察评估。数据收集员使用可穿戴成像技术记录有关电子烟的健康声明。对五类声明进行了拍照:(1)戒烟装置;(2)药物作用/装置;(3)FDA 批准/认可;(4)虚假/误导性和(5)MRTP。对照片进行了双重编码;编码员之间的差异由专家小组裁决并进行了审查。
至少有一个健康声明在 41.3%(n=19)的零售商中显示,每个零售商的声明数量从 0 到 27 不等。发现了所有声明类型。戒烟装置声明最为常见(62.2%,n=84),其次是 MRTP(27.4%,n=37),药物作用/装置(8.1%,n=11),虚假/误导性(1.5%,n=2)和 FDA 批准/认可(0.7%,n=1)。与独立商店相比,零售连锁店做出了大多数声明(88.9%比 11.1%)。
许多蒸气店都展示了电子烟健康声明,而这些声明现在均被 FDA 禁止。这些声明可能会误导消费者并影响行为。研究结果强调了对零售商进行教育,继续进行广告监控,对广告进行执法以及对消费者对声明的看法进行研究的必要性。